Sponsor or institution
Clinical trials and research at Nurix Therapeutics, Inc.
As of November 12, 2026, Find a Trial lists 6 clinical trials run by Nurix Therapeutics, Inc. that are recruiting, at sites in 8 countries (most in United States (6), United Kingdom (3), France (2)). By phase: Phase 1 (3), Phase 3 (1), Phase 2 (1), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 8Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| NX-5948 plus other medicines for B-cell cancers | Phase 1/2 | Aurora, Colorado and 8 other locations | Recruiting | Apr 9, 2026 |
| NX-5948 vs Pirtobrutinib in R/R CLL/SLL | Phase 3 | Macon, Georgia and 5 other locations | Recruiting | Apr 7, 2026 |
| NX-5948 treatment for adults with CLL or SLL after prior BTK and BCL-2 inhibitor therapy | Phase 2 | Phoenix, Arizona and 42 other locations | Recruiting | Oct 28, 2025 |
| Evaluating NX-5948 for advanced B-cell cancers | Phase 1 | Duarte, California and 61 other locations | Recruiting | Nov 23, 2021 |
| Evaluating NX-1607 for advanced cancers | Phase 1 | Duarte, California and 16 other locations | Recruiting | Nov 4, 2021 |
| Evaluating NX-2127 for adults with advanced B-cell cancers | Phase 1 | Duarte, California and 15 other locations | Recruiting | Apr 2, 2021 |
All recruiting trials (6)
-
NX-5948 plus other medicines for B-cell cancers
This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.
-
NX-5948 vs Pirtobrutinib in R/R CLL/SLL
This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.
-
NX-5948 treatment for adults with CLL or SLL after prior BTK and BCL-2 inhibitor therapy
NX-5948, an oral BTK degrader, will be tried to see if it helps adults with relapsed or refractory CLL or SLL who have already been treated with both BTK and BCL-2 inhibitors.
-
Evaluating NX-5948 for advanced B-cell cancers
This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.
-
Evaluating NX-1607 for advanced cancers
This study is testing a new treatment called NX-1607 to see if it can help people with advanced cancers who have run out of other options.
-
Evaluating NX-2127 for adults with advanced B-cell cancers
This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.
Quick answers
How many clinical trials run by Nurix Therapeutics, Inc. are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 8 countries. The most sites are in United States (6 trials), United Kingdom (3 trials), France (2 trials), Italy (2 trials), Poland (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 3: 1, Phase 2: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.